

BLX-301: Optimized Anti-CD20 Antibody

Description

- LEX System optimized
 - Fully human glycosylation structure
 - No fucose (stable RNAi technology)

Opportunity

- Rituxan sales \$3.7 billion
 - Non-Hodgkin's lymphoma
 - Rheumatoid arthritis


Best in Class

- ADCC activity:
 - 20X efficacy
 - 200X potency
- CDC (side effects):
 - 10X reduction

LEX Optimized Rituximab - Head-to-Head Demonstration of Key Properties Engineered into BLX-301

Efficacy & Potency

LEX Optimized Rituximab Shows Enhanced ADCC Activity



Side Effects

LEX Optimized Rituximab Shows Reduced CDC Activity

